Nippon Shinyaku Valuation

Q: What is the Fair Price of NPNK.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

NPNK.F ($41.82) is trading below our estimate of [[fair value]] ($72.54)

Is NPNK.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NPNK.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NPNK.F ($41.82) is trading below our estimate of fair value ($72.54)

Significantly Below Fair Value: NPNK.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NPNK.F?

Key metric: As NPNK.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NPNK.F. This is calculated by dividing NPNK.F's market cap by their current earnings.
What is NPNK.F's PE Ratio?
PE Ratio	16.1x
Earnings	JP¥23.31b
Market Cap	JP¥376.23b

NPNK.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.1x
Enterprise Value/EBITDA	8.9x
PEG Ratio	2.4x

Price to Earnings Ratio vs Peers

How does NPNK.F's PE Ratio compare to its peers?

The above table shows the PE ratio for NPNK.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	17.7x
SUPN Supernus Pharmaceuticals	33.5x	36.2%	US$2.0b
AMPH Amphastar Pharmaceuticals	13.9x	6.7%	US$2.2b
OGN Organon	3x	-7.1%	US$3.9b
PBH Prestige Consumer Healthcare	20.4x	5.4%	US$4.2b
NPNK.F Nippon Shinyaku	16.1x	6.8%	US$376.2b

Price-To-Earnings vs Peers: NPNK.F is good value based on its Price-To-Earnings Ratio (16.1x) compared to the peer average (21.6x).

Price to Earnings Ratio vs Industry

How does NPNK.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

8 Companies	Price / Earnings	Estimated Growth	Market Cap
NDOI Endo	0.6x	n/a	US$1.87b
PROC Procaps Group	2x	n/a	US$103.80m
KPRX Kiora Pharmaceuticals	1.8x	-40.4%	US$10.11m
EDXC Endexx	0.8x	n/a	US$5.34m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: NPNK.F is good value based on its Price-To-Earnings Ratio (16.1x) compared to the US Pharmaceuticals industry average (26.7x).

Price to Earnings Ratio vs Fair Ratio

What is NPNK.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NPNK.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	16.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NPNK.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

0.6%

9.8%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

4.7%

-4.8%